NCT01904773 - Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions

Tourette Syndrome

Interventions

DRUG

AZD5213 and placebo

low dose AZD5213 capsules; high dose AZD5213 capsules; placebo capsules

Trial Locations (7)

Research Site, Orange

Research Site, St. Petersburg

Research Site, Summit

Research Site, New York

Research Site, Cincinnati

Research Site, Orem

Research Site, Salt Lake City